- •New data on the predictors of progression for PPMS are needed for prognostification.
- •We verified the effect of onset age on disease progression rate.
- •Onset with spinal motor symptoms was identified as a negative prognostic factor.
- •Onset with supratentorial signs was associated with a longer time to EDSS6.
- •Presence of gadolinium enhancing lesions was not associated with outcome.
Studies on the predictors of progression for primary progressive multiple sclerosis (PPMS) are limited and there is no information in the literature for populations outside Europe and North America. In this study, we aimed to identify predictors of progression in a large Turkish PPMS cohort.
We analyzed a cohort of 157 PPMS patients to investigate the effect of age of onset, gender, onset symptoms, presence or absence of relapses, and baseline gadolinium-enhancing lesions on the rate of progression to EDSS6 by using Kaplan-Meier analysis and multivariate Cox regression.
Older age of onset and presence of spinal motor symptoms at onset were associated with a shorter time to EDSS6 and presence of supratentorial signs at onset was associated with a longer time to EDSS6 according to Kaplan-Meier analysis. These factors remained significant after multivariate Cox-regression analysis. Clinical relapses were present in 22.3% and gadolinium-enhancing lesions on baseline MRI were present in 28% of patients, but these factors were not predictive of time to EDSS6.
We identified age of onset and symptom at onset as predictors of progression in Turkish PPMS patients. Presence of clinical relapses or baseline gadolinium-enhancing lesions did not affect PPMS progression rate.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Multiple Sclerosis and Related Disorders
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Multiple sclerosis that is progressive from the time of onset: clinical characteristics and progression of disability.Arch. Neurol. 1999; 56: 1138-1142
- Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process.Brain. 2003; 126: 770-782
- Relapses and progression of disability in multiple sclerosis.N. Engl. J. Med. 2000; 343: 1430-1438
- The natural history of multiple sclerosis: a geographically based study. 5. the clinical features and natural history of primary progressive multiple sclerosis.Brain. 1999; 122: 625-639
- Multiple sclerosis with a progressive course from onset in Lorraine-eastern France.J. Neurol. 2007; 254: 1370-1375
- Modelling the natural history of primary progressive multiple sclerosis.J. Neurol. Neurosurg. Psychiatry. 2015; 86: 13-19
- Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial.Ann. Neurol. 2009; 66: 460-471
- Is inflammation important in early PPMS? a longitudinal MRI study.J. Neurol. Neurosurg. Psychiatry. 2005; 76: 1255-1258
- A proposed modification to the Mcdonald 2010 criteria for the diagnosis of primary progressive multiple sclerosis.Mult. Scler. 2013; 19: 1095-1100
- The natural history of primary progressive multiple sclerosis.Neurology. 2009; 73: 1996-2002
- The natural history of early versus late disability accumulation in primary progressive MS.J. Neurol. Neurosurg. Psychiatry. 2015; 86: 615-621
- Evidence for a two-stage disability progression in multiple sclerosis.Brain. 2010; 133: 1900-1913
- Ocrelizumab versus placebo in primary progressive multiple sclerosis.N. Engl. J. Med. 2017; 376: 209-220
- Relapses and disability accumulation in progressive multiple sclerosis.Neurology. 2015; 84: 81-88
- Progression rates and sample size estimates for PPMS based on the climb study population.Mult. Scler. 2015; 21: 180-188
- The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects.Ther. Adv. Neurol. Disord. 2016; 9: 44-52
- Validating predictors of disease progression in a large cohort of primary-progressive multiple sclerosis based on a systematic literature review.PLoS ONE. 2014; 9: e92761
- Preferential spinal cord volume loss in primary progressive multiple sclerosis.Mult. Scler. 2019; 25: 947-957
- Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis.Mult. Scler. 2013; 19: 188-198
- Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial.Ann. Neurol. 2007; 61: 14-24
Published online: November 12, 2019
Accepted: November 10, 2019
Received in revised form: November 7, 2019
Received: May 25, 2019
© 2019 Elsevier B.V. All rights reserved.